Simon Bissonnette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simon Bissonnette has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- May Faraj
Faculty of Medicine, Université de Montréal, Montréal, Canada
4 shared publications Yannick Cyr
Faculty of Medicine, Université de Montréal, Montréal, Canada
4 shared publications- Michel Chrétien
Ottawa Health Research Institute, Ottawa, Canada
3 shared publications - Valerie Lamantia
Faculty of Medicine, Université de Montréal, Montréal, Canada
3 shared publications Gaétan Mayer
Department of Pediatrics and Adolescent Medicine Ulm University Hospital Ulm Germany
2 shared publications- Marie-Françoise Devaux
UR1268 BIA, INRAE, 44316 Nantes, France
2 shared publications
Latest Publications
- Open Access
- 1 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-18
Native low-density lipoproteins are priming signals of the NLRP3 inflammasome/interleukin-1β pathway in human adipose tissue and macrophages
Elevated plasma numbers of atherogenic apoB-lipoproteins (apoB), mostly as low-density lipoproteins (LDL), predict diabetes risk by unclear mechanisms. Upregulation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) system in white adipose tissue (WAT) is implicated in type 2 diabetes (T2D); however, metabolic signals that stimulate it remain unexplored. We hypothesized that (1) subjects with high-apoB have higher WAT IL-1β-secretion than subjects with low-apoB, (2) WAT IL-1β-secretion is associated with T2D risk factors, and (3) LDL prime and/or activate the WAT NLRP3 inflammasome. Forty non-diabetic subjects were assessed for T2D risk factors related to systemic and WAT glucose and fat metabolism. Regulation of the NLRP3 inflammasome was explored using LDL without/with the inflammasome’s priming and activation controls (LPS and ATP). LDL induced IL1B-expression and IL-1β-secretion in the presence of ATP in WAT and macrophages. Subjects with high-apoB had higher WAT IL-1β-secretion independently of covariates. The direction of association of LDL-induced WAT IL-1β-secretion to T2D risk factors was consistently pathological in high-apoB subjects only. Adjustment for IL-1β-secretion eliminated the association of plasma apoB with T2D risk factors. In conclusion, subjects with high-apoB have higher WAT IL-1β-secretion that may explain their risk for T2D and may be related to LDL-induced priming of the NLRP3 inflammasome.ClinicalTrials.gov (NCT04496154): Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood—Full Text View—ClinicalTrials.gov.
- 1 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-18
Open AccessNative low-density lipoproteins are priming signals of the NLRP3 inflammasome/interleukin-1β pathway in human adipose tissue and macrophages
Elevated plasma numbers of atherogenic apoB-lipoproteins (apoB), mostly as low-density lipoproteins (LDL), predict diabetes risk by unclear mechanisms. Upregulation of the NLRP3 inflammasome/interleukin-1 beta (IL-1β) system in white adipose tissue (WAT) is implicated in type 2 diabetes (T2D); however, metabolic signals that stimulate it remain unexplored. We hypothesized that (1) subjects with high-apoB have higher WAT IL-1β-secretion than subjects with low-apoB, (2) WAT IL-1β-secretion is associated with T2D risk factors, and (3) LDL prime and/or activate the WAT NLRP3 inflammasome. Forty non-diabetic subjects were assessed for T2D risk factors related to systemic and WAT glucose and fat metabolism. Regulation of the NLRP3 inflammasome was explored using LDL without/with the inflammasome’s priming and activation controls (LPS and ATP). LDL induced IL1B-expression and IL-1β-secretion in the presence of ATP in WAT and macrophages. Subjects with high-apoB had higher WAT IL-1β-secretion independently of covariates. The direction of association of LDL-induced WAT IL-1β-secretion to T2D risk factors was consistently pathological in high-apoB subjects only. Adjustment for IL-1β-secretion eliminated the association of plasma apoB with T2D risk factors. In conclusion, subjects with high-apoB have higher WAT IL-1β-secretion that may explain their risk for T2D and may be related to LDL-induced priming of the NLRP3 inflammasome.ClinicalTrials.gov (NCT04496154): Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood—Full Text View—ClinicalTrials.gov.
- Open Access
- 1 February 2021
- Published by Wiley in Physiological Reports
- Vol. 9 (3) , e14721
Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
Background LDL‐cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflamma...
- 1 February 2021
- Published by Wiley in Physiological Reports
- Vol. 9 (3) , e14721
Open AccessLower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
Background LDL‐cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflamma...
White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity
Objective: Human conditions with upregulated receptor uptake of low‐density lipoproteins (LDL) are associated with diabetes risk, the reasons for which remain unexplored. LDL induce metabolic dysfunction in murine adipocytes. Thus, it was hypothesized that white adipose tissue (WAT) surface expression of LDL receptor (LDLR) and/or CD36 is associated with WAT and systemic metabolic dysfunction. Whether WAT LDLR and CD36 expression is predicted by plasma lipoprotein‐related parameters was also explored.Methods: This was a cross‐sectional analysis of 31 nondiabetic adults (BMI > 25 kg/m2) assessed for WAT surface expression of LDLR and CD36 (immunohistochemistry), WAT function, WAT and systemic inflammation, postprandial fat metabolism, and insulin resistance (IR; hyperinsulinemic‐euglycemic clamp).Results: Fasting WAT surface expression of LDLR and CD36 was negatively associated with WAT function (3H‐triglyceride storage, r = −0.45 and −0.66, respectively) and positively associated with plasma IL‐1 receptor antagonist (r = 0.64 and 0.43, respectively). Their expression was suppressed 4 hours postprandially, and reduced LDLR was further associated with IR (M/Iclamp, r = 0.61 women, r = 0.80 men). Plasma apolipoprotein B (apoB)‐to‐PCSK9 ratio predicted WAT surface expression of LDLR and CD36, WAT dysfunction, WAT NLRP3 inflammasome priming and disrupted cholesterol‐sensing genes, and systemic IR independent of sex and body composition.Conclusions: Higher fasting and lower postprandial WAT surface expression of LDLR and CD36 is associated with WAT dysfunction, systemic inflammation, and IR in adults with overweight/obesity, anomalies that are predicted by higher plasma apoB‐to‐PCSK9 ratio.
White Adipose Tissue Surface Expression of LDLR and CD36 is Associated with Risk Factors for Type 2 Diabetes in Adults with Obesity
Objective: Human conditions with upregulated receptor uptake of low‐density lipoproteins (LDL) are associated with diabetes risk, the reasons for which remain unexplored. LDL induce metabolic dysfunction in murine adipocytes. Thus, it was hypothesized that white adipose tissue (WAT) surface expression of LDL receptor (LDLR) and/or CD36 is associated with WAT and systemic metabolic dysfunction. Whether WAT LDLR and CD36 expression is predicted by plasma lipoprotein‐related parameters was also explored.Methods: This was a cross‐sectional analysis of 31 nondiabetic adults (BMI > 25 kg/m2) assessed for WAT surface expression of LDLR and CD36 (immunohistochemistry), WAT function, WAT and systemic inflammation, postprandial fat metabolism, and insulin resistance (IR; hyperinsulinemic‐euglycemic clamp).Results: Fasting WAT surface expression of LDLR and CD36 was negatively associated with WAT function (3H‐triglyceride storage, r = −0.45 and −0.66, respectively) and positively associated with plasma IL‐1 receptor antagonist (r = 0.64 and 0.43, respectively). Their expression was suppressed 4 hours postprandially, and reduced LDLR was further associated with IR (M/Iclamp, r = 0.61 women, r = 0.80 men). Plasma apolipoprotein B (apoB)‐to‐PCSK9 ratio predicted WAT surface expression of LDLR and CD36, WAT dysfunction, WAT NLRP3 inflammasome priming and disrupted cholesterol‐sensing genes, and systemic IR independent of sex and body composition.Conclusions: Higher fasting and lower postprandial WAT surface expression of LDLR and CD36 is associated with WAT dysfunction, systemic inflammation, and IR in adults with overweight/obesity, anomalies that are predicted by higher plasma apoB‐to‐PCSK9 ratio.
- 1 June 2018
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 32, 123
Native LDL are Priming Signals of White Adipose Tissue NLRP3 Inflammasome in Overweight and Obese Subjects
- 1 June 2018
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 32, 123
Native LDL are Priming Signals of White Adipose Tissue NLRP3 Inflammasome in Overweight and Obese Subjects